# Self-supervised large-scale kidney abnormality detection in drug safety assessment studies

arXiv: https://arxiv.org/abs/2509.00131 · HTML: https://mlsanity.com/paper/2509.00131/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 4 of its 16 references that are in the map.
- First posted on arXiv 29 Aug 2025.

## Builds on (most cited first, 4 of 4)

- [Deep Residual Learning for Image Recognition](https://mlsanity.com/paper/1512.03385/) (2015)
- [Squeeze-and-Excitation Networks](https://mlsanity.com/paper/1709.01507/) (2017)
- [k-Sparse Autoencoders](https://mlsanity.com/paper/1312.5663/) (2013)
- [Learning image representations for anomaly detection: application to discovery of histological alterations in drug development](https://mlsanity.com/paper/2210.07675/) (2022)

## Abstract (arXiv)

Kidney abnormality detection is required for all preclinical drug development. It involves a time-consuming and costly examination of hundreds to thousands of whole-slide images per drug safety study, most of which are normal, to detect any subtle changes indicating toxic effects. In this study, we present the first large-scale self-supervised abnormality detection model for kidney toxicologic pathology, spanning drug safety assessment studies from 158 compounds. We explore the complexity of kidney abnormality detection on this scale using features extracted from the UNI foundation model (FM) and show that a simple k-nearest neighbor classifier on these features performs at chance, demonstrating that the FM-generated features alone are insufficient for detecting abnormalities. We then demonstrate that a self-supervised method applied to the same features can achieve better-than-chance performance, with an area under the receiver operating characteristic curve of 0.62 and a negative predictive value of 89%. With further development, such a model can be used to rule out normal slides in drug safety assessment studies, reducing the costs and time associated with drug development.